This article summarized the latest R&D progress of Frovatriptan Succinate, the Mechanism of Action for Frovatriptan Succinate, and the drug target R&D trends for Frovatriptan Succinate.

DPP-4 inhibitors enhance the incretin effect by inhibiting DPP-4.

Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is Germany's largest industrial group.

Data analysis from a sample of 822 patients reveals noticeable mepolizumab in symptomatology among Mepolizumab-treated adult asthma sufferers a year post-treatment, regardless of the existence of concomitant medical conditions.

This article summarized the latest R&D progress of Fremanezumab-VFRM, the Mechanism of Action for Fremanezumab-VFRM, and the drug target R&D trends for Fremanezumab-VFRM.

Aldosterone can enhance the sensitivity of vascular smooth muscle to vasoconstrictive substances, indirectly causing other diseases in the body.

Arvinas, Inc. is a biopharmaceutical company that was founded in 2013 and is based in Connecticut, United States.

Carisma Therapeutics's primary candidate product, CT-0508, is set to be displayed at this year's 8th annual CAR-TCR conference.

This article summarized the latest R&D progress of Drotaverine Hydrochloride, the Mechanism of Action for Drotaverine Hydrochloride, and the drug target R&D trends for Drotaverine Hydrochloride.

CaN, or Calcineurin, plays a crucial role in the human body as a calcium-dependent protein phosphatase.

Argenx SE is a biopharmaceutical company that was founded in 2008 and is based in Zuid-Holland, Netherlands.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has initiated dosing of the first patients in its ongoing REVERTIPF trial.